These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23018845)

  • 1. Successful desensitization to imiglucerase of an adult patient diagnosed with type I Gaucher disease.
    Erdoğdu D; Gelincik A; Canbaz B; Colakoğlu B; Büyüköztürk S; Tanakol R
    Int Arch Allergy Immunol; 2013; 160(2):215-7. PubMed ID: 23018845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective desensitization to imiglucerase in a patient with type I Gaucher disease.
    Peroni DG; Pescollderungg L; Piacentini GL; Cassar W; Boner AL
    J Pediatr; 2009 Dec; 155(6):940-1. PubMed ID: 19914435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful rapid desensitization to imiglucerase in an adult patient with Gaucher disease and documented IgE-mediated hypersensitivity.
    Tsilochristou O; Gkavogiannakis NA; Ioannidou EN; Makris M
    J Allergy Clin Immunol Pract; 2015; 3(4):624-6. PubMed ID: 25609344
    [No Abstract]   [Full Text] [Related]  

  • 4. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
    J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
    Latre P; Giraldo P
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K; Richards S; Yee J; Smith SE; Kingma W
    Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaphylactoid reaction to imiglucerase, but not to alglucerase, in a type I Gaucher patient.
    Aviner S; Levy Y; Yaniv I; Cohen IJ
    Blood Cells Mol Dis; 1999 Apr; 25(2):92-4. PubMed ID: 10389590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL
    Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
    Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
    J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
    Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk.
    Sekijima Y; Ohashi T; Ohira S; Kosho T; Fukushima Y
    Clin Ther; 2010 Nov; 32(12):2048-52. PubMed ID: 21118740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.
    Berger J; Vigan M; Pereira B; Nguyen TT; Froissart R; Belmatoug N; Dalbiès F; Masseau A; Rose C; Serratrice C; Pers YM; Bertchansky I; Camou F; Bengherbia M; Bourgne C; Caillaud C; Pettazzoni M; Berrahal A; Stirnemann J; Mentré F; Berger MG
    Clin Pharmacokinet; 2019 Apr; 58(4):469-482. PubMed ID: 30128966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM; Rosenbloom B; Weinreb N; Goker-Alpan O; Grabowski G; Cohn GM; Zahrieh D
    Genet Med; 2014 May; 16(5):359-66. PubMed ID: 24263462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
    Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
    Heitner R; Arndt S; Levin JB
    S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme replacement therapy "drug holiday": results from an unexpected shortage of an orphan drug supply in Australia.
    Goldblatt J; Fletcher JM; McGill J; Szer J; Wilson M
    Blood Cells Mol Dis; 2011 Jan; 46(1):107-10. PubMed ID: 20684886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.